key: cord-0980459-prner4cp authors: Salonia, Andrea; Pontillo, Marina; Capogrosso, Paolo; Gregori, Silvia; Tassara, Michela; Boeri, Luca; Carenzi, Cristina; Abbate, Costantino; Cignoli, Daniele; Ferrara, Anna Maria; Cazzaniga, Walter; Rowe, Isaline; Ramirez, Giuseppe A.; Tresoldi, Cristina; Mushtaq, Junaid; Locatelli, Massimo; Santoleri, Luca; Castagna, Antonella; Zangrillo, Alberto; De Cobelli, Francesco; Tresoldi, Moreno; Landoni, Giovanni; Rovere‐Querini, Patrizia; Ciceri, Fabio; Montorsi, Francesco title: Severely low testosterone in males with COVID‐19: A case‐control study date: 2021-03-09 journal: Andrology DOI: 10.1111/andr.12993 sha: 6f12164d80a4d345ddd0b164db85959c276bdbd9 doc_id: 980459 cord_uid: prner4cp BACKGROUND: Circulating androgens could have a relevant pathobiological role in clinical outcomes in men with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection (COVID‐19). OBJECTIVES: We aimed to assess: (a) circulating sex steroids levels in a cohort of 286 symptomatic men with laboratory‐confirmed COVID‐19 at hospital admission compared to a cohort of 281 healthy men; and (b) the association between serum testosterone levels (tT), COVID‐19, and clinical outcomes. MATERIALS AND METHODS: Demographic, clinical, and hormonal values were collected for all patients. Hypogonadism was defined as tT ≤9.2 nmol/l. The Charlson Comorbidity Index (CCI) was used to score health‐significant comorbidities. Severe clinical outcomes were defined as patients either transferred to intensive care unit (ICU) or death. Descriptive statistics and multivariable linear and logistic regression models tested the association between clinical and laboratory variables and tT levels. Univariable and multivariable logistic regression models tested the association between tT and severe clinical outcomes. RESULTS: Overall, a significantly lower levels of LH and tT were found in patients with COVID‐19 compared to healthy controls (all p < 0.0001); conversely, healthy controls depicted lower values of circulating E(2) (p < 0.001). Testosterone levels suggestive for hypogonadism were observed in 257 (89.8%) patients at hospital admission. In as many as 243 (85%) cases, hypogonadism was secondary. SARS‐CoV‐2 infection status was independently associated with lower tT levels (p < 0.0001) and greater risk of hypogonadism (p < 0.0001), after accounting for age, BMI, CCI, and IL‐6 values. Lower tT levels were associated with higher risk of ICU admission and death outcomes (all p ≤ 0.05), after accounting for clinical and laboratory parameters. CONCLUSIONS: We unveil an independent association between SARS‐CoV‐2 infection status and secondary hypogonadism already at hospital admission, with lower testosterone levels predicting the most severe clinical outcomes. The new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced disease (COVID-19) may lead to a complex clinical picture associated with viral multiorgan tropism. 1 Overall, male individuals are more susceptible to the infection than females, 2,3 and have a higher death rate regardless of age. 4 Reasons for sex disparity in COVID-19 severity might be linked to a number of mechanisms associated with the pathogenesis of viral infections, along with biological host factors (eg, sex differences in terms of susceptibility to viral infection and adaptive immune responses). [4] [5] [6] Of relevance, type and importance of any immune response strongly rely on the biologic sex (ie, genetic predisposition, circulating sex hormones, and surface/intracellular sex hormone receptors). 5,7-10 Thus, sexrelated hormonal milieu might have a significant pathophysiological role after SARS-CoV-2 infection in terms of immune response, viralinduced multiorgan dysregulation, COVID-19-associated clinical severity, and mortality. 10, 11 Moreover, coronavirus entry into host cells is mediated by the transmembrane spike (S) glycoprotein, which needs to be primed to interact with viral receptor angiotensin-converting enzyme 2 (ACE2). SARS-CoV-2 utilizes cell surface protease transmembrane serine protease 2 (TMPRSS2) for viral S protein priming. Both ACE2 and TMPRSS2 are androgen-regulated. 9, [12] [13] [14] [15] Furthermore, ACE2 expression levels were found to be higher in males than in females, at least in the lungs. 16 Likewise, an expression patterns analysis of ACE2 in adult human testes indicated that ACE2 is predominantly enriched in spermatogonia, Leydig, and Sertoli cells, [16] [17] [18] [19] where the receptor is even 3-fold more expressed than in type II alveolar epithelial cells. 16 Based on the hypothesis that hormone-related biological sex differences may have a relevant impact throughout COVID-19 course, we aimed to (a) investigate the levels of circulating total testosterone (tT) and the rate of patients with tT levels suggestive for hypogonadism 20 in a large cohort of symptomatic SARS-CoV-2 infected male patients compared to a cohort of healthy men; (b) test the association between SARS-CoV-2 infection with tT values and hypogonadism status; and (c) assess the prevalent type of hypogonadism, as well as the likelihood of severe clinical outcomes according to clinical parameters and hormonal levels. Data from a cohort of 286 symptomatic male patients with quantitative RT-PCR laboratory-confirmed SARS-CoV-2 infection, that had not yet taken any steroids or antivirals, and either suggestive chest radiography or computed tomography appearances referred for hospital admission between February 29 th and May 2 nd , 2020, at a single academic hospital were analyzed. Data collection followed the principles outlined in the Declaration of Helsinki. All methods were performed in accordance with the relevant guidelines and regulations. On obtaining written individual patient's consent, clinical data from all patients were retrieved using a dedicated case report form, according to an institutional protocol (Covid-BioB, ClinicalTrials.gov NCT04318366; Ethical Committee approval number 34/int/2020). 21 The Charlson Comorbidity Index (CCI) was used to score healthsignificant comorbidities, coded using the International Classification (ICU) or death. Descriptive statistics and multivariable linear and logistic regression models tested the association between clinical and laboratory variables and tT levels. Univariable and multivariable logistic regression models tested the association between tT and severe clinical outcomes. Results: Overall, a significantly lower levels of LH and tT were found in patients with COVID-19 compared to healthy controls (all p < 0.0001); conversely, healthy controls depicted lower values of circulating E 2 (p < 0.001). Testosterone levels suggestive for hypogonadism were observed in 257 (89.8%) patients at hospital admission. In as many as 243 (85%) cases, hypogonadism was secondary. SARS-CoV-2 infection status was independently associated with lower tT levels (p < 0.0001) and greater risk of hypogonadism (p < 0.0001), after accounting for age, BMI, CCI, and IL-6 values. Lower tT levels were associated with higher risk of ICU admission and death outcomes (all p ≤ 0.05), after accounting for clinical and laboratory parameters. We unveil an independent association between SARS-CoV-2 infection status and secondary hypogonadism already at hospital admission, with lower testosterone levels predicting the most severe clinical outcomes. COVID-19, male, SARS-CoV-2, testosterone of Diseases, 10 th revision. 22 Complete data from 309 voluntary healthy blood male donors (aged >18 years) asymptomatic for SARS-CoV-2 infection who consecutively arrived between June 10th and July 23rd, 2020, to the blood donor center of the same hospital were analyzed. According to our research protocol (ethics committee approval number 91/ int/2020), healthy controls underwent the same comprehensive clinical and biochemical assessment of the infected counterpart. Of all, 28 healthy controls were excluded since we found SARS-CoV-2 S1/S2 IgM (n = 15, 4.9%) and SARS-CoV-2 S1/S2 IgG (n = 26, 8.4%) positive serological tests, respectively. Baseline venous blood samples were drawn in all patients at hospital admission (between 7 AM and 11 AM, after an overnight fast), 20 and kept at 4°C until serum or plasma were separated by centrifugation. Serum and plasma aliquots were then stored at -80°C until assay. The same experimental protocol was applied in healthy controls. For the specific purposes of this analysis, on each sample, for every patient at baseline, we measured follicle-stimulating hormone (FSH), luteinizing hormone (LH), tT, and 17β-estradiol (E 2 ). To reflect common practice of a clinical pathology laboratory, we elected to measure circulating hormones using commercially available analytical methods. In all participants, FSH, LH, tT, and E 2 were Likewise, LIAISON ® SARS-CoV-2 S1/S2 IgM and LIAISON ® SARS-CoV-2 S1/S2 IgG serological tests were used to assess SARS-CoV-2 IgM and IgG in every participant. Primary outcomes were overall rate of patients with tT levels suggestive for hypogonadism (according to a tT threshold of 27 The secondary outcome was the association between tT values and severe clinical outcomes (ie, need for ICU admission or death). Lastly, the association between tT levels and severe clinical outcomes (ICU admission or death) was tested with logistic regression models. We hypothesized that the association between disease severity and the risk of death could vary according to the various tT levels; therefore, an interaction term was included in the logistic regression model to test this hypothesis. (Table 2) . Moreover, SARS-CoV-2 infection status was found to significantly predict tT levels suggestive for hypogonadism almost 6 times more than healthy status (p < 0.0001), followed by BMI, age, and IL-6 values (all p ≤ 0.02), at multivariable logistic regression analyses, after adjusting for CCI ( Table 2) . Levels of tT and LH suggestive for secondary, primary, and compensated hypogonadism were found in 243 (85%), 25 (8.8%), and 3 (1%) patients with COVID-19, respectively (Table 3 ). Levels of tT were lower in men belonging to more severe outcome groups (groups 3 and 4) compared to patients in groups 1 and 2 (all Table 3 ). At univariable analyses, tT was inversely associated with ICU admission (p < 0.0001) and death outcomes (p < 0.002) ( Table 4) . At multivariable analyses, considering tT as a parameter of COVID-19 severity at hospital admission, tT levels were associated both with the need of ICU admission and death outcomes (all p ≤ 0.05) ( Table 4 ). The interaction test performed to assess the hypothesis that circulating tT levels could differently impact on the risk of death according to COVID-19 severity, revealed a significant correlation (p = 0.04): the lower the tT levels, the higher the risk of death for the same Critical-Ill COVID-19 score (Figure 1 ). TA B L E 4 Univariable logistic regression models testing the association between clinical and laboratory variables and compulsory need for ICU admission or death in the whole cohort resulting from viral infection. 5, 9, 36 Third and opposite, a background condition of chronic low T levels -which is estimated to characterize up to 20% of middle-aged/elderly men 27 -may facilitate overall greater incidence, higher severity, and greater probability of fatal events in men compared to women. 5 Fourth, SARS-CoV-2 needs androgen-regulated proteins to invade host cells, including TMPRSS2 for S priming and ACE2 for viral entry, which are expressed in multiple tissue 9, 14, 37, 38 ; thereof, the high ACE2 expression in spermatogonia, Leydig, and Sertoli cells may eventually explain the case of a functional dysregulation in T production 28, 29 and spermatogenesis 39 neurotropism. 44 We also showed that serum E 2 levels were higher among patients with severe COVID-19 outcomes as compared with those with less severe clinical conditions. Overall, although it is necessary to underline that laboratory kits may not be as accurate in determining circulating E2 values -or at least less than they are for tT -and therefore, current findings must be taken with adequate caution, high E 2 levels are known to be associated with death in the critically ill patients, regardless of gender. 45 Moreover, not only high E 2 levels at admission but also E 2 changes from baseline in critically ill or injured adults have been demonstrated to be independently associated with mortality. 46 with COVID-19 at younger age, with lower amount of comorbid conditions, and with better severity outcomes (Table 3) . Moreover, current findings showed that SARS-CoV-2 infection status per se was independently associated with lower tT levels, after adjusting for recognized confounders of established hypogonadism (Table 2) . Still, larger studies are needed to assess if the degree of HPG axis suppression correlates with COVID-19 in men, or with the severity of any incidental acute illness, thus including viral infections. As a consequence, current findings might reflect the scenario in which serum tT levels are simply a marker of (any) acute ill health without playing a pathogenic role in SARS-CoV-2 infection. Third, this study is part of an institutional protocol which lacks a pre-infection hormonal milieu assessment in men with COVID-19; in this context, notwithstanding all patients in our cohort had been immediately drawn at hospital admission before any specific medical treatment was implemented, and the baseline assessment has accomplished the most severe inclusion criteria in terms of blood sampling and collection; previous data reported that low circulating T was observed in mechanically ventilated patients with primary ARDS and may contribute to longer ICU stay 47 and in men with critical illness. 35, 48 Fourth, we did not consider smoking cigarette among the potential recognized risk factors for outcomes severity in patients with COVID-19, although the literature recently reported not unambiguous findings. [49] [50] [51] Finally, we cannot exclude that using different thresholds for hypogonadism 52 our results would have been different; however, we have adopted one of the most established definition of low tT that is endorsed by the Endocrine Society. 20 Our findings indicate that most men seeking medical care for symptomatic COVID-19 show low circulating T levels already at the time of hospital admission, which were associated with more severe clinical outcomes. In as many as 85% of cases, sex-hormones levels were suggestive for a condition of secondary hypogonadism. Overall, our case-control study outlines that T levels in males with COVID-19 deserve clinical attention, although it remains to be rigorously established whether T is simply a marker of ill health or measuring it may help to target very high-risk population, while establishing effective counter-active therapeutic measures. Roberto Buccione, PhD (Head, Research Integrity Office, IRCCS Ospedale San Raffaele, Milan, Italy), who checked for similarity index throughout the manuscript. The authors have declared that no conflict of interest exists. Extrapulmonary manifestations of COVID-19 Covid-19: Male disadvantage highlights the importance of sex disaggregated data Hidden in plain sight: sex and gender in global pandemics Considering how biological sex impacts immune responses and COVID-19 outcomes Sex differences in inflammation, redox biology, mitochondria and autoimmunity SeXX and COVID-19: tussle between the two The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system The X chromosome and sex-specific effects in infectious disease susceptibility Sex steroids skew ACE2 expression in human airway: a contributing factor to sex differences in COVID-19? Sex Differences in COVID-19: Candidate Pathways, Genetics of ACE2, and Sex Hormones Androgen Signaling Regulates SARS-CoV-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms in Men Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532) ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy scRNA-seq Profiling of Human Testes Reveals the Presence of the ACE2 Receptor, A Target for SARS-CoV-2 Infection in Spermatogonia Histopathology and Ultrastructural Findings of Fatal COVID-19 Infections on Testis The ACE2 expression in Sertoli cells and germ cells may cause male reproductive disorder after SARS-CoV-2 infection Pathological Findings in the Testes of COVID-19 Patients: Clinical Implications Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline Fast reshaping of intensive care unit facilities in a large metropolitan A new method of classifying prognostic comorbidity in longitudinal studies: development and validation Acute Respiratory Distress Syndrome Severity scoring of lung oedema on the chest radiograph is associated with clinical outcomes in ARDS Initial chest radiographs and artificial intelligence (AI) predict clinical outcomes in COVID-19 patients: analysis of 697 Italian patients Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19 Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study Low testosterone levels predict clinical adverse outcomes in SARS-CoV-2 pneumonia patients Evaluation of sex-related hormones and semen characteristics in reproductive-aged male COVID-19 patients Effect of serum total testosterone and its relationship with other laboratory parameters on the prognosis of coronavirus disease, (COVID-19) in SARS-CoV-2 infected male patients: a cohort study SARS-CoV-2 Pneumonia Affects Male Reproductive Hormone Levels: A Prospective. Cohort Study Understanding the Complex Relationship Between Androgens and SARS-CoV2 SARS-CoV-2, testosterone and frailty in males (PROTEGGIMI): A multidimensional research project Sex differences in severity and mortality from COVID-19: are males more vulnerable? Paediatric and adult-onset male hypogonadism Understanding immune effects of oestrogens to explain the reduced morbidity and mortality in female versus male COVID-19 patients. Comparisons with autoimmunity and vaccination Sex differences in COVID-19: the role of androgens in disease severity and progression Multi-organ proteomic landscape of COVID-19 autopsies Impaired spermatogenesis in COVID-19 patients Semen impairment and occurrence of SARS-CoV-2 virus in semen after recovery from COVID-19. Hum Reprod Sex hormone alterations and systemic inflammation in chronic obstructive pulmonary disease Hypogonadotropic hypogonadism in human immunodeficiency virus-infected men: uncommonly low testosterone levels. Endocrinol Diabetes Metab Case Rep Low testosterone and high cytokine levels correlate with lethal H7N9 infections in men: a retrospective cohort study from 98 H7N9 patients Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms Estradiol is associated with mortality in critically ill trauma and surgical patients Trends in Estradiol During Critical Illness are Associated with Mortality Independent of Admission Estradiol Low Testosterone Levels are Frequent in Patients with Acute Respiratory Failure and are Associated with Poor Outcomes Endocrine evaluation of patients with critical illness Features of severe COVID-19: A systematic review and meta-analysis Nicotinic Cholinergic System and COVID-19. In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications Smoking Prevalence and COVID-19 in Europe Challenges in Testosterone Measurement, Data Interpretation, and Methodological Appraisal of Interventional Trials Severely low testosterone in males with COVID-19: A case-control study